Aimmune Therapeutics (AIMT) PT Raised to $45 at JMP Securities
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Join SI Premium – FREE
JMP Securities raised its price target on Aimmune Therapeutics (NASDAQ: AIMT) to $45.00 (from $40.00) while maintaining a Market Outperform rating.
Analyst Liisa Bayko said strong efficacy and safety data in the Phase 3 PALISADE trial de-risks shares and bodes well for approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VRTX) PT Raised to $615 at UBS
- Five9, Inc (FIVN) PT Raised to $33 at DA Davidson on Growth Outlook, AI Benefits
- Safehold (SAFE) PT Lowered to $13 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
